Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients

2020 ◽  
Author(s):  
Noé R Montanari ◽  
Nádia Conceição-Neto ◽  
Ilse Van Den Wyngaert ◽  
Gertine W Van Oord ◽  
Zwier M A Groothuismink ◽  
...  
Keyword(s):  
Gene Expression ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Inactive Carrier ◽  
B Virus ◽  
Infected Liver ◽  
Differential Gene ◽  
Chronic Hbv

Abstract Long-term viremia control in chronic HBV patients occurs either spontaneously in inactive carrier (IC) patients or therapy-induced by nucleos(t)ide analogues (NUC). To better understand the characteristics of viremia control, we evaluated gene expression in purified leukocyte subsets from IC versus NUC-treated patients, and evaluated the putative modulatory effects of hepatitis B surface antigen (HBsAg). We observed that gene expression in NUC-treated patients differed markedly from IC patients, especially in dendritic cells, monocytes, and CD8+ T cells, while serum HBsAg levels had little effect. Nevertheless, based on our findings it cannot be excluded that HBsAg may act locally in the infected liver or preferentially affects HBV-specific cells.

Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients

2011 ◽  
Vol 18 (10) ◽  
pp. e468-e474 ◽  
Author(s):  
A. Gramenzi ◽  
E. Loggi ◽  
L. Micco ◽  
C. Cursaro ◽  
S. Fiorino ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Serum Hepatitis ◽  
B Virus

scholarly journals Binding of biotin to hepatitis B surface antigen: a possible pitfall in immunohistochemistry.

1989 ◽  
Vol 37 (4) ◽  
pp. 551-554 ◽  
Author(s):  
J J van den Oord ◽  
F Facchetti ◽  
C de Wolf-Peeters ◽  
V J Desmet
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Disulfide Bonds ◽  
Hepatitis B Surface Antigen ◽  
B Virus ◽  
Infected Liver ◽  
Hepatitis B Viral Infection ◽  
Positive Results

We report on the binding of biotin, and hence of biotinylated antibodies and lectins, to ground glass hepatocytes and liver cell membranes in chronic hepatitis B viral infection. This binding is of low affinity, and was proved to be directed at the hepatitis B surface antigen, presumably at its disulfide bonds. To avoid false-positive results, this affinity should be considered in the interpretation of immunohistochemical stainings of hepatitis B virus-infected liver tissue with biotinylated reagents.

scholarly journals Human polyclonal anti-hepatitis B surface antigen immunoglobulin reduces the frequency of acute rejection after liver transplantation for chronic hepatitis B

2001 ◽  
Vol 43 (6) ◽  
pp. 335-337 ◽  
Author(s):  
Claudia Alves COUTO ◽  
Paulo Lisboa BITTENCOURT ◽  
Alberto Queiroz FARIAS ◽  
Margareth Pauli LALLEE ◽  
Eduardo Luiz Rachid CANÇADO ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Protective Role ◽  
Group Iii ◽  
Group I ◽  
B Virus ◽  
Group Ii

BACKGROUND: Use of polyclonal anti-hepatitis B surface antigen immunoglobulin (HBIg) has been shown to reduce hepatitis B virus (HBV) recurrence after liver transplantation (LT) and to decrease the frequency of acute cellular rejection (ACR). However, the protective role of HBIg against ACR remains controversial, since HBV infection has been also associated with a lower incidence of ACR. AIM: To assess the relationship between HBIg immunoprophylaxis and the incidence of rejection after LT. METHODS: 260 patients (158 males, 43 ± 14 years old) submitted to LT were retrospectively evaluated and divided into three groups, according to the presence of HBsAg and the use of HBIg. Group I was comprised of HBsAg-positive patients (n = 12) that received HBIg for more than 6 months. Group II was comprised of HBsAg-positive patients that historically have not received HBIg or have been treated irregularly for less than 3 months (n = 10). Group III was composed of 238 HBsAg-negative subjects that have not received HBIg. RESULTS: HBIg-treated patients (group I) had significantly less ACR episodes, when compared to group II and III. No differences between groups II and III were observed. CONCLUSIONS: Long-term HBIg administration contributes independently to reduce the number of ACR episodes after LT.

scholarly journals Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers

2018 ◽  
Vol 17 (2) ◽  
pp. 232-241 ◽  
Author(s):  
Conar R. O’Neil ◽  
Stephen E. Congly ◽  
M. Sarah Rose ◽  
Samuel S. Lee ◽  
Meredith A. Borman ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
North American ◽  
Hepatitis B Surface Antigen ◽  
Long Term Follow Up ◽  
Chronic Hbv

Rates and determinants of hepatitis B ‘e’ antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus

AIDS ◽  
2015 ◽  
Vol 29 (15) ◽  
pp. 1963-1973 ◽  
Author(s):  
Anders Boyd ◽  
Joël Gozlan ◽  
Patrick Miailhes ◽  
Caroline Lascoux-Combe ◽  
Manuela Sébire-Le Cam ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B E Antigen ◽  
B Virus ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document